Influx Healthtech IPO – Comprehensive Analysis (June 2025)
Influx Healthtech Ltd, a fast-growing Mumbai-based healthcare CDMO, is all set to launch its IPO this June. Here’s a detailed, fact-based analysis covering everything from company background to financials, strengths, risks, and IPO details.
🏢 Company Overview
Founded: 2020
Headquarters: Mumbai, Maharashtra
Business Model: CDMO (Contract Development and Manufacturing Organisation)
Sectors Served:
- Nutraceuticals
- Cosmetics
- Ayurvedic & Herbal Formulations
- Veterinary Feed Supplements
- Homecare Products
Key Offerings:
- Multi-nutritional tablets
- Oral dispersible films
- Capsules, powders, liquids, softgels, creams
- Gummy candies
Certifications:
- GMP (Good Manufacturing Practices)
- HACCP
- ISO 22000:2018 (Food Safety Management)
- ISO 14001:2015 (Environmental Management)
- Halal Certification
- FDA Approval
Manufacturing Location: Palghar, Thane, Maharashtra
Promoter & Managing Director: Mr. Munir Abdul Ganee Chandniwala
Client Base:
Spans cosmetics, pharmaceutical, home care, and veterinary industries with B2B partnerships.
📅 IPO Timeline
| Event | Date / Details |
|---|---|
| IPO Opening Date | 18 June 2025 |
| IPO Closing Date | 20 June 2025 |
| Price Band | ₹91 – ₹96 |
| Lot Size | 1,200 shares |
| Minimum Investment | ₹1,09,200 |
| Issue Size | ₹58.57 Crores |
| Issue Type | Fresh Issue |
📈 Financial Performance (₹ in Crores)
| Financial Year | Revenue | Profit (PAT) |
|---|---|---|
| FY23 | ₹76.06 Cr | ₹7.20 Cr |
| FY24 | ₹99.96 Cr | ₹11.13 Cr |
| FY25 | ₹104.85 Cr | ₹13.37 Cr |
🔍 Industry & Peer Comparison
Sector: CDMO (Healthcare & Nutraceuticals)
Key Peers:
- Tirupati Medicare
- Natco Pharma (in broader segment)
- Akums Drugs & Pharma (private)
Sector Positioning:
Influx operates in a high-growth CDMO market, especially within India’s booming nutraceutical space. However, with a single-location model and significant regional reliance (Maharashtra), its geographical and client concentration is higher than diversified peers.
✅ Strengths
- 🧪 Diverse Product Portfolio: Tablets, softgels, powders, oral films, Ayurvedic and veterinary products
- 🏭 Certified Manufacturing Facilities: GMP, HACCP, ISO, and Halal
- 📈 Consistent Financial Growth: PAT grew from ₹7.2 Cr to ₹13.37 Cr in 3 years
- 🧠 In-House R&D: Specialized formulation development for faster product cycles
- 🌐 Multi-Sector Presence: Serves cosmetics, pharma, nutraceutical, and home care industries
⚠️ Risks & Concerns
- 📍 Geographical Concentration: 60–67% of revenue from Maharashtra
- 👥 Customer Concentration Risk: Top 10 customers contribute ~47–50% of total revenue
- 🔗 Supplier Dependence: Top 10 suppliers account for ~36–39% of raw materials
- 📉 Heavy Reliance on Nutraceuticals: >89% revenue from this segment
- 💰 Raw Material Price Volatility: No long-term contracts with suppliers
- ⚖️ Legal Proceedings: Ongoing cases involving promoters and company entities
📄 IPO Document
Please refer to the official Red Herring Prospectus (RHP) for complete details – [RHP PDF – Influx Healthtech Ltd]
📌 Disclaimer
This analysis is based on publicly available information including the DRHP, RHP, and SEBI/Exchange filings. It is intended purely for informational purposes and does not constitute investment advice. Investors should conduct their own due diligence or consult a SEBI-registered advisor before making investment decisions. Read the Disclaimer page for more details.